Answers are grounded in this paper and cite their sources.
Euglycemic diabetic ketoacidosis (euDKA) is a rare but life-threatening complication in users of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor prescribed for type 2 diabetes mellitus (T2DM), where normal or mildly elevated blood glucose levels (<200–250 mg/dL) frequently delay clinical recognition. This narrative literature review aimed to identify the clinical patterns and reporting frequency of precipitating factors accompanying diabetic ketoacidosis (DKA and euDKA) in patients treated with empagliflozin, rather than estimating epidemiological risk. A structured search was conducted on PubMed for English-language case reports with full text available published between January 1, 2016, and September 15, 2026, using the query (empagliflozin OR "SGLT2 inhibitor") AND ("diabetic ketoacidosis" OR "euglycemic diabetic ketoacidosis"). Study selection followed the PRISMA 2020 flow diagram and the PEO (Population, Exposure, Outcome) framework, conducted independently by two reviewers with consensus resolution by a third reviewer, yielding 18 eligible case reports. Methodological quality was appraised using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case Reports (15 high quality, 3 moderate quality). Through hybrid thematic coding, precipitating factors were organized hierarchically into three mechanistic domains comprising seven categories, and the proportion of included case reports reporting each factor (reporting frequency) was calculated; a single case report could involve multiple overlapping triggers. The highest reporting frequencies were observed for carbohydrate restriction and inadequate nutritional intake (13/18 reports; 72.2%), perioperative periods, medical procedures, and fasting (8/18; 44.4%), and acute infections (7/18; 38.9%), followed by the initial phase of therapy ≤2 months (6/18; 33.3%), insulin deficiency (5/18; 27.8%), endocrine comorbidities and malignancies (4/18; 22.2%), and non-infectious acute events (4/18; 22.2%). In conclusion, DKA/euDKA in empagliflozin users is multifactorial, driven by the interplay between drug-induced glucosuria and acute carbohydrate depletion, catabolic stress, or insulinopenia. Because case reports lack a population denominator and are subject to publication bias, these reporting frequencies reflect clinical trigger patterns rather than comparative clinical risk.
No takes yet. Share an insight, caveat, or question.
Putri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: